Intentar ORO - Gratis
The Future Formula: What's Driving Recruitment Innovation in Pharma
BioSpectrum Asia
|BioSpectrum Asia August 2025
The pharmaceutical recruitment process is becoming more organised, strategic, and data-driven, adapting to changing demands and needs.
The pharmaceutical and life sciences industry has been undergoing a transformation driven by rapid technological change, demographic shifts, regulatory complexity, and globalisation over the last five years. This shift is especially visible in areas like data science, clinical development, regulatory affairs and digital trials, where the pace of progress demands both depth and flexibility. As organisations respond to faster product cycles and increasingly specialised needs, pharma companies are not behind. Capability-based hiring is becoming central to how they build and manage their teams.
To support this, many companies are deploying focused hiring teams for specific functions such as clinical operations, safety monitoring, and product launch support. These teams, often structured through modular partnerships, allow organisations to access niche talent and expertise at speed without having the need to have a long-term Talent acquisition team. This approach has helped reduce time to hire by 33 per cent and cost to hire by 36 per cent, which is especially valuable when hiring delays risk impacting regulatory timelines or market readiness.
RPOs and Embedded Talent Partners Are Enabling Agility
Recruitment Process Outsourcing (RPO) firms and embedded talent partners are playing a growing role in helping pharma companies stay responsive to shifting demands. By acting as integrated extensions of internal HR teams, these partners are improving hiring speed, ensuring consistency in experience and enabling access to global candidate pools. Their involvement is especially effective in supporting high-growth or expansion markets, where internal teams may not have the capacity or reach.
New Talent Pools Are Emerging in Tier 2 & 3 Cities
Esta historia es de la edición BioSpectrum Asia August 2025 de BioSpectrum Asia.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE BioSpectrum Asia
BioSpectrum Asia
India Health Fund supports D-Nome to bolster molecular TB screening in India
India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform
BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
NTU and NHG Health partner to advance healthcare education in Singapore
NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan
Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
How FemTech Spurt in APAC is Redefining Healthcare
Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.
4 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
China's Colossal Ageing Population and Low Birth Rate Challenge
China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.
2 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"
At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.
7 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area
Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"
More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.
5 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel
Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
1 min
BioSpectrum Asia May 2026
Listen
Translate
Change font size
